Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Berman

Showing results (411-420 of 459) with videos related to

Pageof 46
Sort By:
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri, Jennifer A Low, James J Lee, et al.
Journal of Virology|December 1, 1987
T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzeesJ W Eichberg, J M Zarling, H J Alter, et al.
Journal of Cellular Biochemistry|October 28, 1999
Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activatorC Köhne, A Johnson, S Tom, et al.
Journal of Virology|October 1, 1993
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1G R Nakamura, R Byrn, D M Wilkes, et al.
AIDS Research and Human Retroviruses|November 14, 1998
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3D P Francis, T Gregory, M J McElrath, et al.
The Journal of Infectious Diseases|February 1, 1995
Trypanosoma cruzi induces endothelin release from endothelial cellsM Wittner, G J Christ, H Huang, et al.
Frontiers in Medicine|October 12, 2016
Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected IndividualsDina Tsukrov, Alicia McFarren, Alfred Morgenstern, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 28, 2018
Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell ImmunityBlake F Frey, Jiansheng Jiang, Yongjun Sui, et al.
AIDS Research and Human Retroviruses|October 28, 2006
Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trialDavid V Jobes, Melissa Daoust, Vivian T Nguyen, et al.
Pageof 46

Showing results (411-420 of 459) with videos related to

Sort By:
Pageof 46
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri, Jennifer A Low, James J Lee, et al.
Journal of Virology|December 1, 1987
T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzeesJ W Eichberg, J M Zarling, H J Alter, et al.
Journal of Cellular Biochemistry|October 28, 1999
Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activatorC Köhne, A Johnson, S Tom, et al.
Journal of Virology|October 1, 1993
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1G R Nakamura, R Byrn, D M Wilkes, et al.
AIDS Research and Human Retroviruses|November 14, 1998
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3D P Francis, T Gregory, M J McElrath, et al.
The Journal of Infectious Diseases|February 1, 1995
Trypanosoma cruzi induces endothelin release from endothelial cellsM Wittner, G J Christ, H Huang, et al.
Frontiers in Medicine|October 12, 2016
Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected IndividualsDina Tsukrov, Alicia McFarren, Alfred Morgenstern, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 28, 2018
Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell ImmunityBlake F Frey, Jiansheng Jiang, Yongjun Sui, et al.
AIDS Research and Human Retroviruses|October 28, 2006
Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trialDavid V Jobes, Melissa Daoust, Vivian T Nguyen, et al.
Pageof 46